Information  X 
Enter a valid email address

Physiomics PLC (PYC)

  Print      Mail a friend

Thursday 06 June, 2013

Physiomics PLC

Virtual Tumour Clinical Contract

RNS Number : 3847G
Physiomics PLC
06 June 2013



Physiomics plc

The Magdalen Centre

The Oxford Science Park

Robert Robinson Avenue





Tel 01865 784980

Fax 08701 671931

5th June 2013                           

Physiomics plc

("Physiomics") or ("the Company")


Physiomics signs contract for Virtual Tumour Clinical and data analysis services


Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed  a contract with a biotechnology company to apply its new Virtual Tumour Clinical platform to their lead compound.  The biotechnology company will pay an up-front technology access fee now and ongoing service fees as the project progresses.  This represents the first commercial deal for Physiomics' flagship Virtual Tumour Clinical technology. The project will commence immediately.

Physiomics' emerging Virtual Tumour Clinical technology will be used in conjunction with traditional PK/PD techniques to guide the dosing and scheduling of the biotechnology company's lead molecule in the clinic.


Dr Mark Chadwick, CEO of Physiomics, commented:

"We are delighted to start the first commercial Virtual Tumour Clinical project.  Each new project that we complete will allow us to improve and extend the model and make it applicable to more oncology projects in future."



Physiomics plc                                                  

Dr Mark Chadwick, CEO

+44 (0)1865 784 980



WH Ireland Limited (broker/nomad)

Katy Mitchell

+44 (0) 161 832 2174




About Physiomics plc


Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.


Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.


Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit


SystemCell® is a registered trademark of Physiomics plc

1Tufts Centre Impact Report 2002


This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t